Brief: Vicore Provides Update Regarding Phase 1 Study Of C106

Vicore Pharma Holding AB

27/10/2023 07:24

Oct 27 (Reuters) - Vicore Pharma Holding AB  VICOR.ST :
    * VICORE PROVIDES UPDATE REGARDING PHASE 1 STUDY OF C106
    * WHILE NO MAJOR SAFETY SIGNAL WAS OBSERVED WITH C106, A
REPORTED
INCREASE IN BLOOD PRESSURE REPRESENTS A CHALLENGE TO FURTHER
DEVELOPMENT
    * DEVELOPMENT OF C21 CONTINUES AS PLANNED WITH SIGNIFICANT
CLINICAL DEVELOPMENT TO DATE WITHOUT ANY BLOOD PRESSURE SIGNAL

Source text for Eikon:  ID:nMFN4J04zb 
Further company coverage:  VICOR.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))